| Table Of Content |
Section I - Background and early development
The discovery of sumatriptan and a new class of drugs for the acute treatment of migraine, Humphrey
5-HT receptors in brain and vasculature, Hargreaves & Beer
Structural and operational diversity of Serotonin receptors. Potential relevance to migraine pathophysiology and treatment, Martin
Characterisation of 5-HT1 receptor expression in human vasculature, Mosley, Mansfield & McHarg
5-HT1B and 5-HT1D receptor immunoreactivity colocalize with sensory neurotransmitters in the human trigeminal ganglion, , Hou, Kanje, Tajti, Uddman & Edvinsson
Upregulation of 5-HT1B/1D receptors during organ culture of cerebral arteries, Hoel, Hansen-Schwartz & Edvinsson
Background and early development - discussion summary, Olesen
Section II - Pharmacology of the triptans
Clinical pharmacokinetics of the triptans:what are the important clinical issues?, Millson
Pharmacodynamics of triptans, Saxena
Characteristics of different routes of administration, Dahlof
Encapsulation of sumatriptan does not delay its absorption, Milton, Kleinermans, Scott & Cooper
Synergism of 5-HT1 and 5-HT2 receptors in sumatriptan-induced vasocontractile response in rabbit common carotid artery, Akin, Onaran & Gurdal
Role of 5-HT1B and 5HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery, Akin & Gurdal
Comparison of triptan induced contractions in human cerebral vs coronary arteries, Uddman & Edvinsson
Pharmacological analysis of cotractile effects of eletriptan and sumatriptan on human isolated blood vessels, van den Broek, Maassen vandenbrink,de Vries, Avezaat & Saxena
Pharmacology of the triptans: discussion summary, Humphrey
Section III - Antimigraine actions of the triptans
The importance of vasoconstriction in the mechanism of the antimigraine action of the triptans, Feniuk & Humphrey
Inhibition of neurogenic inflammation is most important, Buzzi
Central nervous system effects are most important, Goadsby
Do we really understand how triptans work?, Olesen
The relevance of hepatic intrinsic clearance and brain penetration on the doses used for 5-HT agonists (triptans) in the treatment of migraine, Morgan, McCleverty, McHarg & Milton
In vivo serotonergic effects and extracellular brain levels of centrally and systemically administered eletriptan, zolmitriptan and sumatriptan, Rollema, Johnson, Schmidt & McHarg
Regulation of capsaicin-evoked CGRP release from rat dural sensory neurones in vitro, Feniuk, Jarvie & Humphrey
Arterial distensibility in ergotamine and sumatriptan abuse, Evers, Barenbrock & Husstedt
Anti migraine actions of the triptans: discussion summary, Hargreaves
Section IV - Clinical efficacy and tolerability of the triptans
Sumatriptan: looking back and looking forward, Mansback
Zolmitriptan offers doctor and patient choices for effective treatment of migraine, Torres
Rizatriptan: clinical update, Allen
Evidence against tight correlation between chest oppressive symptoms and ischaemic coronary changes after subcutaneous sumatriptan injection, Tomita, Suzuki, Igarashi, Endo & Sakai
Alteration in cluster headache during subcutaneous administration of sumatriptan, Hering-Hanit
Efficacy and tolerability of rizatriptan 10mg in migraine: experience with 70527 patient episodes, Gobel, Heinze, Heinze-Kuhn & Lindner
Consistency of pain relief over multiple migraine attacks following treatment with rizatriptan, Dahlof, Lipton, Lines, Kramer, Reines, Polis & Ferrari
Naratriptan: the gentle triptan, Salonen
Experience with eletriptan (RelpaxTM), Jackson
Almotriptan, Pascual
Frovatriptan: simplifying clinical practice in migraine, Keywood
The cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack, Elkind, McDaris, Satin & Keywood
Lack of clinically significant interactions between frovatriptan and ergotamine, propranolol or moclobemide, Buchan, Ward, Oliver, Stewart & Freestone
Frovatriptan pharmocokinetics are unaffected during a migraine attack, Buchan, Ward & Zeig
Clinical efficacy and tolerability of the triptans: discussion summary, Ferrari
Section V - The triptans in clinical practice
Acute management of migraine: clinical trials of triptans versus other agents, Lipton & Goadsby
Which triptans for which patient?, Tfelt-Hansen
The Framig 99 survey III: therapeutical behaviour of migraineurs, Lucas, Lanteri-Minet & Leroy
Migraine in France in 2000: therapeutical data, Lucas, Lanteri-Minet, Auray, Duru, Chazot, Dartigues, Henry, Pradalier, El Hasnaouia & Gaudin
The triptan threshold score: a score tohelp patients identify the best moment to take the triptan, Gobel, Heinze, Heinze-Kuhn, Austermann, Chryssafopoulos & Keil
Triptan plus NSAID with long half life: increase of efficacy and reduction of headache recurrence in acute migraine, Gobel, Heinze, Heinze-Kuhn & Zumbroich
Comparison of the triptans with other drugs in the development of drug-induced headache, Gobel, Heinze, Heinze-Kuhn & Zumbroich
An epidemiological study on the differences between sumatriptan and ergotamine overuse, Evers, Gralow, Bauer, Suhr, Buchheister & Husstedt
Overuse of new 5-HT agonists (zolmitriptan and naratriptan) in migraine patients: clinical features, Lanteri-Minet, Alchaar, Coullet & Chatel
The triptans in clinical practice: discussion summary, Goadsby
|
